PDF icon Download PDF
Thromb Haemost
DOI: 10.1055/a-2628-3967
Stroke, Systemic or Venous Thromboembolism

Direct Oral Anticoagulants for Prevention of Venous Thromboembolism after Cancer-related Surgery: Systematic Review and Network Meta-analysis

Gerardo N. Pititto‡   *
1   Internal Medicine Residency Program, School of Medicine, University of Insubria, Varese and Como, Italy
,
Giorgio Maraziti‡   *
2   Internal, Vascular and Emergency Medicine - Stroke Unit, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy
,
Alessandro Squizzato 
3   Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria - ASST Lariana, Como, Italy
,
Cecilia Becattini
2   Internal, Vascular and Emergency Medicine - Stroke Unit, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy
› Author Affiliations
› Further Information
   Permissions and Reprints


Preview

Abstract

Background

The risk of venous thromboembolism (VTE) is high after cancer surgery and is reduced by antithrombotic prophylaxis.

Material and Methods

We conducted a systematic review and network meta-analysis to evaluate the effectiveness and safety of direct oral anticoagulants (DOACs) for VTE prophylaxis after cancer surgery. The primary study outcome was 30-day VTE after surgery. Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were estimated.

Results

Five randomized controlled trials (RCTs; two gynecological, one abdominal, one neurosurgical, and one thoracic; 1,694 patients) and seven observational studies (three urological, two abdominal, and two gynecological; 2,042 patients) were included. DOACs reduced the incidence of 30-day (OR 0.52, 95% CI 0.27-0.98, I2 22.7%) and 90-day VTE (OR 0.51, 95% CI 0.28-0.92, I2 0%) compared to LMWH. No difference was observed between DOACs and LMWH in 30 and 90-day bleeding outcomes. In random effect analyses, apixaban (OR 0.31, 95% CI 0.11-0.84) and not rivaroxaban reduced the risk of 30 day-VTE compared to LMWH (OR 0.69, 95% CI 0.35-1.34) without increasing the risk of bleeding at 30 or 90 days. No difference in the risk of VTE or bleeding was observed between DOACs and placebo/no treatment, but these analyses were probably underpowered. Subgroup analyses were conducted on LMWH pre-treatment, extended prophylaxis, duration of surgery, and type of surgery.

Conclusion

Our study supports apixaban and rivaroxaban as promising alternatives to LMWH in post-operative prophylaxis of VTE after cancer surgery. Further high-quality data are needed in specific surgical settings.

Keywords

venous thromboembolism - cancer surgery - network meta-analysis - direct oral anticoagulants - antithrombotic prophylaxis

Data Availability Statement

All data generated or analyzed during this study are included in this article or its supplementary material files. The study protocol is available on PROSPERO (CRD42024500972). Further inquiries can be directed to the corresponding author.


Authors' Contribution

G.N.P., G.M., and C.B. prepared the study concept. G.N.P., G.M., and C.B. performed study selection and data extraction. G.N.P., G.M., A.S., and C.B. wrote and reviewed the full article. G.M. performed statistical analysis.


* These authors contributed equally to this study.


Supplementary Material



Publication History

Received: 20 January 2025

Accepted: 04 June 2025

Accepted Manuscript online:
05 June 2025

Article published online:
25 June 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist 2017; 22 (02) 199-207
    CrossrefPubMedSearch in Google Scholar
  • 2 De Martino RR, Goodney PP, Spangler EL. et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg 2012; 55 (04) 1035-1040.e4
    CrossrefPubMedSearch in Google Scholar
  • 3 Merkow RP, Bilimoria KY, McCarter MD. et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg 2011; 254 (01) 131-137
    CrossrefPubMedSearch in Google Scholar
  • 4 Agnelli G, Bolis G, Capussotti L. et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006; 243 (01) 89-95
    CrossrefPubMedSearch in Google Scholar
  • 5 Frere C, Font C, Esposito F, Crichi B, Girard P, Janus N. Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. Support Care Cancer 2022; 30 (04) 2919-2931
    PubMedSearch in Google Scholar
  • 6 Bergqvist D, Agnelli G, Cohen AT. et al; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346 (13) 975-980
    CrossrefPubMedSearch in Google Scholar
  • 7 Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P. CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010; 8 (06) 1223-1229
    CrossrefPubMedSearch in Google Scholar
  • 8 Felder S, Rasmussen MS, King R. et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev 2019; 8 (08) CD004318
    PubMedSearch in Google Scholar
  • 9 Falanga A, Ay C, Di Nisio M. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol 2023; 34 (05) 452-467
    CrossrefPubMedSearch in Google Scholar
  • 10 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 2023; 41 (16) 3063-3071
    CrossrefPubMedSearch in Google Scholar
  • 11 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
    CrossrefPubMedSearch in Google Scholar
  • 12 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361 (06) 594-604
    CrossrefPubMedSearch in Google Scholar
  • 13 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375 (9717) 807-815
    CrossrefPubMedSearch in Google Scholar
  • 14 Lassen MR, Ageno W, Borris LC. et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358 (26) 2776-2786
    CrossrefPubMedSearch in Google Scholar
  • 15 Eriksson BI, Borris LC, Friedman RJ. et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358 (26) 2765-2775
    CrossrefPubMedSearch in Google Scholar
  • 16 Anderson DR, Morgano GP, Bennett C. et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv 2019; 3 (23) 3898-3944
    CrossrefPubMedSearch in Google Scholar
  • 17 Guntupalli SR, Brennecke A, Behbakht K. et al. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open 2020; 3 (06) e207410
    CrossrefPubMedSearch in Google Scholar
  • 18 Becattini C, Pace U, Pirozzi F. et al. Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Blood 2022; 140 (08) 900-908
    CrossrefPubMedSearch in Google Scholar
  • 19 Zhou H, Ye LL, Zhou JT, Ma FX, Ma JJ, Zhang JH. Direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: a systematic review and meta-analysis. Surg Endosc 2024; 38 (03) 1131-1138
    PubMedSearch in Google Scholar
  • 20 Zhou H, Chen TT, Ye LL, Ma JJ, Zhang JH. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis. World J Surg Oncol 2024; 22 (01) 69
    PubMedSearch in Google Scholar
  • 21 Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. London: NICE Decision Support Unit Technical Support Documents; 2014
    Search in Google Scholar
  • 22 Efthimiou O, Mavridis D, Debray TP. et al; GetReal Work Package 4. Combining randomized and non-randomized evidence in network meta-analysis. Stat Med 2017; 36 (08) 1210-1226
    CrossrefPubMedSearch in Google Scholar
  • 23 Seide SE, Jensen K, Kieser M. A comparison of Bayesian and frequentist methods in random-effects network meta-analysis of binary data. Res Synth Methods 2020; 11 (03) 363-378
    PubMedSearch in Google Scholar
  • 24 Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 2015; 15: 58
    CrossrefPubMedSearch in Google Scholar
  • 25 Hutton B, Salanti G, Caldwell DM. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162 (11) 777-784
    CrossrefPubMedSearch in Google Scholar
  • 26 Longo de Oliveira ALM, de Oliveira Pereira RF, Agati LB. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after major gynecological cancer surgery: the VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial). Clin Appl Thromb Hemost 2022 ;28:10760296221132556
    PubMedSearch in Google Scholar
  • 27 Wang ZY, Wan YD, Liu XZ, Wang H, Jiang GY, Yang B. A single-center, randomized, double-blind study of 94 patients undergoing surgery for cerebral glioma to compare postoperative thromboprophylaxis with and without rivaroxaban. Med Sci Monit 2022; 28: e934341
    PubMedSearch in Google Scholar
  • 28 Zhao M, Bao Y, Jiang C. et al. Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: a randomized, noninferiority trial. Am J Hematol 2023; 98 (08) 1185-1195
    PubMedSearch in Google Scholar
  • 29 Spénard E, Geerts W, Lin Y. et al. Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy. Gynecol Oncol 2023; 172: 9-14
    PubMedSearch in Google Scholar
  • 30 Rich JM, Elkun Y, Geduldig J. et al. Outcomes from a prospectively implemented protocol using apixaban after robot-assisted radical cystectomy. BJU Int 2023; 132 (04) 390-396
    CrossrefPubMedSearch in Google Scholar
  • 31 Westerman ME, Bree KK, Msaouel P. et al. Apixaban vs enoxaparin for post-surgical extended-duration venous thromboembolic event prophylaxis: a prospective quality improvement study. J Urol 2022; 208 (04) 886-895
    PubMedSearch in Google Scholar
  • 32 Rashid MF, Jackson TL, Morgan JA. et al. Dabigatran (Pradaxa) is safe for extended venous thromboembolism prophylaxis after surgery for pancreatic cancer. J Gastrointest Surg 2019; 23 (06) 1166-1171
    PubMedSearch in Google Scholar
  • 33 Ortiz RM, Golijanin B, O'Rourke TK. et al. Direct oral anticoagulants for venous thromboembolism prophylaxis following robot-assisted radical cystectomy: a retrospective feasibility study at a single academic medical center. Urology 2021; 156: 154-162
    CrossrefPubMedSearch in Google Scholar
  • 34 Kelly K, Blanck LM, Lim K. et al. Apixaban for extended thromboprophylaxis after oncologic resection: outcomes and cost analysis. Am Surg 2023; 89 (12) 5428-5435
    PubMedSearch in Google Scholar
  • 35 Knisely A, Iniesta MD, Batman S. et al. Efficacy, safety, and feasibility of apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center. Gynecol Oncol 2024; 183: 120-125
    PubMedSearch in Google Scholar